Pfizer says its experimental drug for deadly condition that causes appetite and weight loss in cancer patients shows positive trial results

Pfizer says its experimental drug for deadly condition that causes appetite and weight loss in cancer patients shows positive trial results

Pfizer‘s experimental drug for a common, life-threatening condition that causes cancer patients to lose their appetite and weight showed positive results in a midstage trial, the drugmaker said Saturday.  Patients with the condition, called cancer cachexia, who took Pfizer’s treatment saw improvements in body weight, muscle mass, quality of life and physical function, according to…

Read More
Decoding atractylodes lancea: a genomic journey th | Newswise

Decoding atractylodes lancea: a genomic journey th | Newswise

Newswise — The cultivation of high-quality medicinal plants like Atractylodes lancea involves intricate genetic processes influenced by environmental factors. Despite its extensive use in traditional medicine, the genetic basis and metabolomic diversity of A. lancea remain largely unexplored. Growing in varied environments, the plant encounters challenges such as drought and nutrient deficiencies, driving genetic differentiation…

Read More
Eli Lilly to invest .8 billion to expand manufacturing for weight loss, diabetes and Alzheimer’s drugs

Eli Lilly to invest $1.8 billion to expand manufacturing for weight loss, diabetes and Alzheimer’s drugs

A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly on Thursday said it will invest $1.8 billion to boost manufacturing for its newly approved Alzheimer’s drug and highly popular weight loss and diabetes treatments, among other medicines,…

Read More
Alzheimer’s drug Leqembi promises to give patients more time, but they face a long road to treatment

Alzheimer’s drug Leqembi promises to give patients more time, but they face a long road to treatment

Hannah Yoon | The Washington Post | Getty Images Leqembi, an Alzheimer’s drug from Biogen and Eisai, isn’t a cure for the mind-damaging disease.  But the treatment promises to give patients such as Missie Meeks more time to live their daily lives normally and independently of others. Meeks, an English professor based in Ellisville, Mississippi,…

Read More
Risky Combos of Psychiatric Drugs Prescribed for Y | Newswise

Risky Combos of Psychiatric Drugs Prescribed for Y | Newswise

Newswise — A new study reveals that young patients treated with psychiatric medications receive potentially dangerous combinations with concerning frequency. Researchers from Rutgers Health and other institutions analyzed New York State Medicaid records for more than 141,000 patients receiving any psychiatric medication.  Nearly 400 of them received at least one potentially dangerous combination t for…

Read More